Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan · Delayed Price · Currency is TWD 14.85
-0.55 (-3.57%)
Jan 22, 2026, 1:12 PM CST
Meribank Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 486.52 | 366.43 | 234.34 | 180.12 | 163.08 | 194.39 | Upgrade | |
Revenue Growth (YoY) | 85.97% | 56.36% | 30.10% | 10.45% | -16.11% | 20.78% | Upgrade |
Cost of Revenue | 258.02 | 172.49 | 95.47 | 85.35 | 73.02 | 79.25 | Upgrade |
Gross Profit | 228.5 | 193.94 | 138.87 | 94.77 | 90.06 | 115.14 | Upgrade |
Selling, General & Admin | 241.17 | 244.72 | 221.9 | 179.2 | 165.88 | 174.68 | Upgrade |
Research & Development | 36.9 | 35.9 | 35.48 | 25.94 | 16.11 | 6.43 | Upgrade |
Operating Expenses | 281.86 | 281.84 | 261.23 | 204.55 | 187.27 | 185.25 | Upgrade |
Operating Income | -53.36 | -87.9 | -122.36 | -109.78 | -97.22 | -70.11 | Upgrade |
Interest Expense | -20.38 | -10.7 | -0.85 | -0.99 | -1.13 | -0.74 | Upgrade |
Interest & Investment Income | 1.86 | 2.53 | 1.86 | 1.27 | 0.48 | 0.56 | Upgrade |
Earnings From Equity Investments | -10.12 | -11.93 | -5.41 | -5.42 | -4.51 | -0.93 | Upgrade |
Other Non Operating Income (Expenses) | 11.06 | 11.18 | 2.48 | 11.69 | 2.98 | 3.09 | Upgrade |
EBT Excluding Unusual Items | -70.94 | -96.81 | -124.28 | -103.23 | -99.39 | -68.13 | Upgrade |
Impairment of Goodwill | - | - | -5.67 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -4.73 | -4.73 | - | - | 0.18 | - | Upgrade |
Asset Writedown | - | - | - | - | - | 5.86 | Upgrade |
Legal Settlements | - | - | - | - | - | 7.63 | Upgrade |
Other Unusual Items | - | - | - | - | 0.02 | 0.19 | Upgrade |
Pretax Income | -75.67 | -101.55 | -129.95 | -103.23 | -99.19 | -54.46 | Upgrade |
Income Tax Expense | -7.72 | -4.61 | -0.44 | -0.08 | - | - | Upgrade |
Earnings From Continuing Operations | -67.95 | -96.94 | -129.51 | -103.15 | -99.19 | -54.46 | Upgrade |
Minority Interest in Earnings | 1.11 | 2.23 | 4.16 | 1.01 | - | - | Upgrade |
Net Income | -66.84 | -94.71 | -125.35 | -102.13 | -99.19 | -54.46 | Upgrade |
Net Income to Common | -66.84 | -94.71 | -125.35 | -102.13 | -99.19 | -54.46 | Upgrade |
Shares Outstanding (Basic) | 88 | 80 | 63 | 63 | 60 | 53 | Upgrade |
Shares Outstanding (Diluted) | 88 | 80 | 63 | 63 | 60 | 53 | Upgrade |
Shares Change (YoY) | 31.49% | 26.54% | 0.11% | 4.07% | 14.52% | 0.16% | Upgrade |
EPS (Basic) | -0.76 | -1.19 | -1.99 | -1.63 | -1.64 | -1.03 | Upgrade |
EPS (Diluted) | -0.76 | -1.19 | -1.99 | -1.63 | -1.64 | -1.03 | Upgrade |
Free Cash Flow | 35.33 | -286.7 | -35.5 | -45.48 | -30.2 | -25.05 | Upgrade |
Free Cash Flow Per Share | 0.40 | -3.60 | -0.56 | -0.72 | -0.50 | -0.48 | Upgrade |
Gross Margin | 46.97% | 52.93% | 59.26% | 52.62% | 55.22% | 59.23% | Upgrade |
Operating Margin | -10.97% | -23.99% | -52.21% | -60.95% | -59.61% | -36.07% | Upgrade |
Profit Margin | -13.74% | -25.85% | -53.49% | -56.70% | -60.83% | -28.02% | Upgrade |
Free Cash Flow Margin | 7.26% | -78.24% | -15.15% | -25.25% | -18.52% | -12.89% | Upgrade |
EBITDA | 6.97 | -50.76 | -110.86 | -98.08 | -86.11 | -58.56 | Upgrade |
EBITDA Margin | 1.43% | -13.85% | -47.31% | -54.45% | -52.80% | -30.12% | Upgrade |
D&A For EBITDA | 60.33 | 37.14 | 11.49 | 11.7 | 11.11 | 11.55 | Upgrade |
EBIT | -53.36 | -87.9 | -122.36 | -109.78 | -97.22 | -70.11 | Upgrade |
EBIT Margin | -10.97% | -23.99% | -52.21% | -60.95% | -59.61% | -36.07% | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.